EZ1 logo

Enzon Pharmaceuticals BST:EZ1 Stock Report

Last Price

€0.059

Market Cap

€5.4m

7D

-4.0%

1Y

-23.7%

Updated

25 Nov, 2024

Data

Company Financials

Enzon Pharmaceuticals, Inc.

BST:EZ1 Stock Report

Market Cap: €5.4m

Enzon Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enzon Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.059
52 Week HighUS$0.18
52 Week LowUS$0.046
Beta0.54
11 Month Change-8.46%
3 Month Change-46.88%
1 Year Change-23.72%
33 Year Changen/a
5 Year Changen/a
Change since IPO-34.62%

Recent News & Updates

Recent updates

Shareholder Returns

EZ1DE BiotechsDE Market
7D-4.0%-0.2%0.8%
1Y-23.7%-16.9%9.1%

Return vs Industry: EZ1 underperformed the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: EZ1 underperformed the German Market which returned 8.5% over the past year.

Price Volatility

Is EZ1's price volatile compared to industry and market?
EZ1 volatility
EZ1 Average Weekly Movement15.1%
Biotechs Industry Average Movement6.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.8%
10% least volatile stocks in DE Market2.4%

Stable Share Price: EZ1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: EZ1's weekly volatility has decreased from 20% to 15% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1981n/aRick Feinsteinenzon.com

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.

Enzon Pharmaceuticals, Inc. Fundamentals Summary

How do Enzon Pharmaceuticals's earnings and revenue compare to its market cap?
EZ1 fundamental statistics
Market cap€5.37m
Earnings (TTM)€235.34k
Revenue (TTM)€24.77k

21.4x

P/E Ratio

202.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EZ1 income statement (TTM)
RevenueUS$26.00k
Cost of RevenueUS$0
Gross ProfitUS$26.00k
Other Expenses-US$221.00k
EarningsUS$247.00k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.0033
Gross Margin100.00%
Net Profit Margin950.00%
Debt/Equity Ratio0%

How did EZ1 perform over the long term?

See historical performance and comparison